Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 12/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692638 | 0.97 | MCL1 (0.40) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 | |
| SCHEMBL5692743 | 0.95 | MCL1 (0.40) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 | |
| SCHEMBL14307115 | 0.95 | MCL1 (0.40) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 | |
| SCHEMBL5692554 | 0.95 | KDM4E (0.39) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 | |
| SCHEMBL5693283 | 0.90 | ABCC1 (0.38) | MCL1KDM4EALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL5693271 | 0.90 | CYP3A4 (0.49) | MCL1CYP3A4CTSB | |
| SCHEMBL5693275 | 0.89 | CYP3A4 (0.44) | MCL1KDM4EALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL13521416 | 0.89 | CYP3A4 (0.46) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 | |
| SCHEMBL5693290 | 0.89 | ABCC1 (0.38) | MCL1KDM4EALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL12325022 | 0.89 | MCL1 (0.39) | MCL1KDM4EALDH1A1SMN1; SMN2UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | MCL1 2223/4885KDM4E 4649/4885ALDH1A1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.